NIH Clinical Center logo     America's Clinical Research Hospital File folder iconExplore the NIH
Clinical Center
Search the Studies - NIH Clinical Research Studies

Protocol Details

Pilot Study to Assess Biomarkers of Changes in Barrier Function of Skeletal Muscle in Patients with a Fragile Sarcolemmal Muscular Dystrophy

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

13-CH-0112

Sponsoring Institute

National Institute of Child Health and Human Development (NICHD)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18
Max Age: N/A

Referral Letter Required

No

Population Exclusion(s)

Children

Special Instructions

Currently Not Provided

Keywords

Muscle;
Inflammatory Cytokines;
Exercise;
Biomarkers;
Predictors of Outcome

Recruitment Keyword(s)

None

Condition(s)

Genetic Disorder

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Institute of Child Health and Human DevelopmentNational Institute of Neurological Disorders and StrokeNIH Clinical CenterUniversity of Massachusetts Medical School

Background:

- Some kinds of muscular dystrophy affect the skeletal muscle membrane. In these conditions, the muscle membrane is more fragile. This affects how the muscles contract and relax, which causes movement problems. Researchers are looking at several muscle enzymes, or chemicals that affect how muscle cells function. By studying changes in these enzymes, they may be able to better understand how muscular dystrophy affects the cells. Researchers want to collect biomarkers (chemicals from blood samples) from people with fragile sarcolemmal muscular dystrophy. This information may provide better treatments for this condition.

Objectives:

- To study biomarkers that may affect the muscles of people with fragile sarcolemmal muscular dystrophy.

Eligibility:

- Individuals at least 18 years of age with fragile sarcolemmal muscular dystrophy.

Design:

- Participants will be screened with a medical history and physical exam.

- Participants will be asked to come for four visits to the National Institutes of Health Clinical Center. The visits will be at least 2 months apart. Each visit will require participants to stay for 5 days at the clinical center.

- During each visit, participants will provide frequent small blood samples. These samples will be collected while at rest and after physical exercise.

- Participants will also have a physical therapy assessment. They will perform standard motor function tests and imaging tests (MRI, MRS). These tests may take up to 1 hour each time.

- Treatment will not be provided as part of this study.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

-Aged 18 or older

-Have a confirmed genetic diagnosis of one of the FSMDs or have a clinical phenotype consistent with one of the FSMDs

-Be able to travel to the NIH Clinical Center at the NIH for studies

-Able to commit to multiple 5 day stays at the NIH Clinical Center

-Established primary care physician

-Ambulant: able to walk 10 meters or 33 feet without walking aids or orthotics

EXCLUSION CRITERIA:

-Fail to meet the above inclusion criteria

-Are unable or unwilling to be examined

-Adults unable to provide their own consent

-Have active, on-going medical problems such as (e.g. diabetes, hypothyroidism, pancreatitis, anemia, cancer, renal, hepatic, Pulmonary or cardiac disease) or who have undergone recent surgery (i.e. less than 8 days post-surgery)

-Pregnant females

-Currently taking any or a combination of anti-inflammatory drugs, statins or other drugs with known myotoxicity, narcotics


--Back to Top--

Citations:

Bansal D, Campbell KP. Dysferlin and the plasma membrane repair in muscular dystrophy. Trends Cell Biol. 2004 Apr;14(4):206-13. Review.

Cohn RD, Campbell KP. Molecular basis of muscular dystrophies. Muscle Nerve. 2000 Oct;23(10):1456-71. Review.

Wallace GQ, McNally EM. Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu Rev Physiol. 2009;71:37-57. doi: 10.1146/annurev.physiol.010908.163216. Review.

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Joshua J. Zimmerberg, M.D.
National Institute of Child Health and Human Development (NICHD)
National Institutes of Health
Building 10
Room 10D14
10 Center Drive
Bethesda, Maryland 20892
(301) 496-6571
zimmerbj@mail.nih.gov

Joshua J. Zimmerberg, M.D.
National Institute of Child Health and Human Development (NICHD)
National Institutes of Health
Building 10
Room 10D14
10 Center Drive
Bethesda, Maryland 20892
(301) 496-6571
zimmerbj@mail.nih.gov

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

prpl@mail.cc.nih.gov

Clinical Trials Number:

NCT01851447

--Back to Top--

QUESTIONS?

Contact the Patient Recruitment and Public Liaison Office for:

  • Details on how to participate in a study
  • Details on how to refer a patient to a study

NIH Clinical Studies Information Request


Contact the Office of Communications for:

  • General information about the NIH Clinical Center

www.cc.nih.gov/contact.shtml


Contact the Department Clinical Research Informatics, (DCRI) for:

  • Technical questions about Adobe Acrobat and the PDF format
  • Technical questions about this web server

webmaster@cc.nih.gov